SARS-CoV-2 Nucleocapsid MAb (Clone 1035111) Summary
Accession # YP_009724397.2
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of SARS-CoV-2 Nucleocapsid by Western Blot. Western blot shows recombinant SARS-CoV-2 Nucleocapsid protein. PVDF membrane was probed with 2 µg/mL of Mouse Anti-SARS-CoV-2 Nucleocapsid Monoclonal Antibody (Catalog # MAB10474) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for SARS-CoV-2 Nucleocapsid at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.
SARS-CoV-2 Nucleocapsid in SARS-CoV-2 Infected Human Lung. SARS-CoV-2 Nucleocapsid was detected in immersion fixed paraffin-embedded sections of SARS-CoV-2 infected human lung (left, positive staining) and normal human lung (right, negative control) using Mouse Anti-SARS-CoV-2 Nucleocapsid Monoclonal Antibody (Catalog # MAB10474) at 5 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to SARS-CoV-2 infected cells. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). While the S, E and M proteins build up the viral envelop, the N protein is involved transcription, replication and packaging of the viral RNA genome into a helical ribonucleocapsid (RNP) (2, 3). The SARS-CoV-2 N protein is a ~45 kDa protein composed of two independent structural domains connected by a linker region. The N-terminal region contains an RNA binding domain, the linker region interacts with the M protein and the C-terminal region contains a self-association domain (2,3). The SARS-CoV2 N protein shares 91% and 47% amino acid sequence identity with SARS-CoV-1 and MERS N protein, respectively. The SARS-CoV-2 N protein displays VSR (viral suppressor of RNA interference) activity in mammalian cells (4). In addition, the N protein is an abundant protein during coronavirus infection and displays high immunogenic activity (5, 6), so it has been used to develop serological diagnostic kit for Covid-19 IgM and IgG antibody tests (7).
- Wu, F. et al. (2020) Nature 579:265.
- Chang, C. K. et al. (2006) J. Biomed. Sci. 13:59.
- Hurst, K. R. et al. (2009) J. Virol. 83:7221.
- Mu, J. et al. (2020) Sci. China Life Sci. doi: 10.1007/s11427-020-1692-1.
- Che, X. Y. et al. (2004) J. Clin. Microbiol. 42:2629.
- Guan, M. et al. (2004) Clin. Diagn. Lab. Immunol. 11:287.
- Liu, W. et al. (2020) J. Clin. Microbiol. doi: 10.1128/JCM.00461-20.
Citations for SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 4
Filter your results:
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Authors: R Suzuki, D Yamasoba, I Kimura, L Wang, M Kishimoto, J Ito, Y Morioka, N Nao, H Nasser, K Uriu, Y Kosugi, M Tsuda, Y Orba, M Sasaki, R Shimizu, R Kawabata, K Yoshimatsu, H Asakura, M Nagashima, K Sadamasu, K Yoshimura, Genotype t, H Sawa, T Ikeda, T Irie, K Matsuno, S Tanaka, T Fukuhara, K Sato
Sample Types: Whole Tissue
Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody
Authors: T Sulea, J Baardsnes, M Stuible, N Rohani, A Tran, M Parat, Y Cepero Don, M Duchesne, P Plante, G Kour, Y Durocher
PLoS ONE, 2022;17(3):e0266250.
Sample Types: Whole Cells
Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein
Authors: R Otsubo, T Minamitani, K Kobiyama, J Fujita, T Ito, S Ueno, I Anzai, H Tanino, H Aoyama, Y Matsuura, K Namba, KI Imadome, KJ Ishii, K Tsumoto, W Kamitani, T Yasui
Scientific Reports, 2022;12(1):20120.
Sample Types: Whole Tissue
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
Authors: A Saito, T Irie, R Suzuki, T Maemura, H Nasser, K Uriu, Y Kosugi, K Shirakawa, K Sadamasu, I Kimura, J Ito, J Wu, K Iwatsuki-H, M Ito, S Yamayoshi, S Loeber, M Tsuda, L Wang, S Ozono, EP Butlertana, YL Tanaka, R Shimizu, K Shimizu, K Yoshimatsu, R Kawabata, T Sakaguchi, K Tokunaga, I Yoshida, H Asakura, M Nagashima, Y Kazuma, R Nomura, Y Horisawa, K Yoshimura, A Takaori-Ko, M Imai, Genotype t, S Tanaka, S Nakagawa, T Ikeda, T Fukuhara, Y Kawaoka, K Sato
Sample Types: Whole Tissue
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)
There are currently no reviews for this product. Be the first to review SARS-CoV-2 Nucleocapsid MAb (Clone 1035111) and earn rewards!
Have you used SARS-CoV-2 Nucleocapsid MAb (Clone 1035111)?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image